Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2025-01-03 00:00:00 ET · period of report 2025-01-02 · accession 0001415889-25-000676 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-03 | 2025-01-02 | JANX | Winter Charles M. | Chief Technical Off | A - Grant | $0.00 | +23.0K | 77.3K | +42% | $0 |
| D | 2025-01-03 | 2025-01-02 | JANX | Winter Charles M. | Chief Technical Off | A - Grant | $0.00 | +80.5K | 80.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | A | A | 23,000 | $0.00 | 77,288 | D | — | — | (F1) Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. (F2) Includes 1,297 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,644 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023, 2,834 shares acquired under the Plan on May 15, 2024 and 1 share acquired under the Plan on November 15, 2024. |
| 2 | Derivative | Stock option (right to buy) | 2025-01-02 | A | A | 80,500 | $0.00 | 80,500 | D | $53.24 · — to 2035-01-01 | 80,500 Common Stock | (F3) 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. |